What is the new drug for pancreatic cancer called?

The new drug for pancreatic cancer is called elraglusib.

What were the results of the elraglusib clinical trial?

In the clinical trial, patients on elraglusib combined with chemotherapy were twice as likely to survive for one year and saw a 38% reduction in the overall risk of death compared to chemotherapy alone.

How does elraglusib compare to standard chemotherapy for pancreatic cancer?

Elraglusib, when used with chemotherapy, showed doubled one-year survival rates and a 38% reduction in death risk compared to chemotherapy alone.

Home / Health / Breakthrough Drug Shows Promise Against Pancreatic Cancer

Breakthrough Drug Shows Promise Against Pancreatic Cancer

14 Apr

•

Summary

New drug elraglusib combined with chemotherapy may double survival rates.
Patients taking elraglusib saw a 38% reduction in the overall risk of death.
The drug showed promising results in a clinical trial involving 233 patients.

Breakthrough Drug Shows Promise Against Pancreatic Cancer

A groundbreaking drug, elraglusib, developed by researchers at Northwestern University, has demonstrated the potential to significantly improve survival rates for pancreatic cancer patients. In a recent clinical trial involving 233 participants across North America and Europe, combining elraglusib with standard chemotherapy led to a doubling of survival rates after one year.

Patients treated with elraglusib lived an average of 10.1 months, compared to 7.2 months for those receiving chemotherapy alone. This innovative treatment also reduced the overall risk of death by 38%, with 44% of patients alive after one year, a stark contrast to the 22% in the chemotherapy-only group. While side effects were observed and were slightly more common, they were generally reversible, including temporary vision changes.